Treatment Overview

Receiving a diagnosis of testicular cancer can be a profound shock, especially since it predominantly affects younger men who may not have faced serious health issues before. The discovery of a lump or swelling often leads to immediate anxiety about the future, fertility, and sexual health. However, this diagnosis comes with a very hopeful perspective: testicular cancer is one of the most treatable and curable forms of cancer, even when it has spread beyond the testicle. Treatment is vital not only to remove the cancer but to prevent it from traveling to the lymph nodes, lungs, or other organs. 

Because there are different types of testicular cancer mainly seminomas and non-seminomas, treatment plans are highly specific. The approach depends on the exact cell type, the stage of the disease, and whether the cancer has spread to lymph nodes. While surgery is almost always the first step to remove the tumor, additional treatment with medication or radiation is frequently required to ensure all cancer cells are eliminated (National Cancer Institute, 2023). 

Overview of treatment options for Testicular Cancer 

The primary goal of treating testicular cancer is a complete cure. The standard first step for all patients is a radical inguinal orchiectomy, a surgery to remove the affected testicle. For some patients with early-stage disease, this surgery followed by active surveillance (regular scans and blood tests) is the only treatment needed. 

However, if there is a risk of recurrence or if the cancer has spread, medical therapy becomes the cornerstone of care. Medications are used to attack cancer cells that may have traveled elsewhere in the body. Unlike some cancers where medication is used to manage symptoms, here the intent is aggressive and curative. In certain cases of seminoma, radiation therapy may be used, but chemotherapy is the primary medical intervention for advanced cases. 

Medications used for Testicular Cancer 

Medical treatment for testicular cancer relies heavily on powerful chemotherapy regimens. These drugs are usually administered in specific combinations to maximize effectiveness. 

Platinum-based chemotherapy is the most critical drug class used in fighting this disease. Cisplatin is the primary agent and is responsible for the high cure rates associated with testicular cancer. It is almost always used in combination with other drugs. Clinical experience suggests that cisplatin-based regimens can cure the vast majority of patients, even those with metastatic disease. 

Antitumor antibiotics and mitotic inhibitors are typically combined with platinum drugs. A common regimen known as BEP includes bleomycin (an antibiotic that damages cancer DNA) and etoposide (an enzyme inhibitor). These drugs work together to attack cancer cells at different stages of their growth cycle. 

Chemotherapy for testicular cancer requires antiemetics and supportive medications to manage side effects, especially significant nausea and vomiting. Potent anti-nausea drugs, such as serotonin antagonists or corticosteroids, are routinely given for patient comfort. 

How these medications work 

The medications used to treat testicular cancer target the rapid division of cells. Cancer cells are characterized by their inability to stop growing and dividing. 

Chemotherapy agents damage the RNA or DNA that guides cell replication. For example, Cisplatin “handcuffs” cancer cell DNA by creating cross-links, preventing it from unzipping and replicating. If the cell finds its DNA too damaged to repair, it self-destructs. 

Bleomycin breaks DNA strands, while etoposide inhibits an enzyme needed to untangle DNA during division. By using multiple methods to attack the cancer’s reproductive ability, these combinations prevent tumor survival and spread. 

Side effects and safety considerations 

Because chemotherapy attacks all rapidly dividing cells, healthy tissues like hair follicles, the lining of the mouth, and bone marrow are also affected. Chemotherapy for testicular cancer commonly causes hair loss, fatigue, mouth sores, and increased infection risk due to low white blood cell counts. 

Specific drug risks exist: Cisplatin can cause kidney damage and hearing loss (tinnitus), mitigated by extra fluids. Bleomycin carries a risk of lung damage, sometimes requiring avoidance of high oxygen concentrations (e.g., scuba diving) post-treatment. 

Fertility is a key concern, as chemotherapy may permanently reduce sperm counts; sperm banking is highly recommended beforehand. Fever during treatment requires immediate medical attention for urgent antibiotic treatment, as it signals a serious infection (American Cancer Society, 2024). 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. National Cancer Institute. https://www.cancer.gov 
  1. American Cancer Society. https://www.cancer.org 
  1. Mayo Clinic. https://www.mayoclinic.org 
  1. Urology Care Foundation. https://www.urologyhealth.org 

Medications for Testicular Cancer

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Testicular Cancer.

Found 5 Approved Drugs for Testicular Cancer

CISplatin

Generic Name
CISplatin

CISplatin

Generic Name
CISplatin
Form: Injection
Method of administration: Intravenous
FDA approval date: June 01, 2000
Classification: Platinum-based Drug
Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Etopophos

Generic Name
Etoposide

Etopophos

Generic Name
Etoposide
Form: Injection, Capsule
Method of administration: Oral, Intravenous
FDA approval date: May 01, 1996
Classification: Topoisomerase Inhibitor
ETOPOPHOS is a topoisomerase inhibitor indicated for the treatment of patients with: Refractory testicular tumors, in combination with other chemotherapeutic drugs. ( 1 ) Small cell lung cancer, in combination with cisplatin, as first-line treatment. ( 1 )

IFEX

Generic Name
Ifosfamide

IFEX

Generic Name
Ifosfamide
Form: Injection
Method of administration: Intravenous
FDA approval date: December 30, 1988
Classification: Alkylating Drug
Ifosfamide Injection is indicated for use in combination with certain other approved antineoplastic agentsfor third-line chemotherapy of germ cell testicular cancer. It should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. Ifosfamide Injection is an alkylating drug indicated for use in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. It should be used in combination with mesna for prophylaxis of hemorrhagic cystitis.

Dactinomycin

Generic Name
Dactinomycin

Dactinomycin

Generic Name
Dactinomycin
Form: Injection
Method of administration: Intravenous
FDA approval date: July 31, 2019
Classification: Actinomycin
Dactinomycin for injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen.

Citrtae

Brand Names
MiloPhene, Clomid

Citrtae

Brand Names
MiloPhene, Clomid
Form: Tablet
Method of administration: Oral
FDA approval date: September 09, 2022
Classification: Estrogen Agonist/Antagonist
Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS.) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: 1. Patients who are not pregnant. 2. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. 3. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. 4. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: 1. Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. 2. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. 3. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. 4. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. 5. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses.
Showing 1-5 of 5
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances